PLANET MICROCAP TORONTO POWERED BY MICROCAPCLUB - ELECTROCORE INC

Financial Performance:

• Full-year 2025 revenue peaked at approximately $32 million; first six months of 2026 generated $19 million, resulting in a current revenue run rate of ~$40 million.
• The company has achieved 50% compounded annual revenue growth over the last five years.
• Gross profit margins have expanded significantly from the low 70s to the mid-to-high 80s.
• 2024 general wellness revenue was $2.4 million, growing to $5 million in 2025, with plans to prioritize profitability over triple-digit growth in this segment.
• Net debt stands at approximately $7.5 million, scheduled to begin amortization in March 2027.
• The capital structure is described as "clean" with no ratchets, anti-dilutes, or black-scholes warrants; the last two equity deals were unit deals involving insiders and board members.

Guidance and Future Outlook:

• Management targets reaching adjusted EBITDA positivity in the back half of 2027.
• Strategic goals include reducing Sales & Marketing expenses from ~60% of revenue to the industry norm of 40-50%.
• Future growth is driven by expanding beyond the VA to other federal marketplaces (Federal Workers' Comp, active duty military, TRICARE) and commercial partners like Kaiser Permanente.
• The company anticipates significant penetration of the VA market over the next two years, particularly through the new Quell Fibromyalgia product.
• Valuation is viewed as undervalued by management, trading at 1.9x to 2.0x forward revenue compared to a historical mean of 4.5x for similar companies.

Business Segments and Product Lines:

• Prescription Products (Primary Revenue Driver):
  • GammaCore: Non-invasive vagal nerve stimulation (NIVS) device for primary headaches (migraine, cluster headache); holds six FDA clearances; accounts for ~70% of revenue.
  • Quell Fibromyalgia: Acquired via Neurometrics (May 2025); only FDA-approved product for fibromyalgia; revenue grew ~30% sequentially to $1.3 million last quarter; currently sold to 30% of VA accounts, leaving 70% expansion potential.
• General Wellness Products:
  • TruVega: Direct-to-consumer device for sleep, relaxation, and stress management; lower margins than medical devices but supports cash flow.
  • TACSTIM (Tactical Stimulation): Military-spec, white-labeled device developed with Air Force Research Labs for cognitive enhancement and human performance; sold via B2B and DTC channels.
• R&D Pipeline:
  • Filed a 510(k) for chemotherapy-induced peripheral neuropathy (CIPN) with Breakthrough Device Designation; aims to be the first product approved for this indication.
  • Over 30 investigator-initiated trials underway for indications including PTSD, mild TBI, gastroparesis, and stroke recovery.

Market and Competitive Landscape:

• VA Market: Addresses ~600,000 headache patients and ~9.5 million covered lives for PTSD; currently serves only ~3% of the headache population despite selling into 150 of 170 VA Medical Centers.
• Commercial Market: Targets the $101 billion general wellness industry (potentially up to $5 billion depending on scope) and expanded federal markets including Federal Workers' Comp.
• Competitive Advantage: GammaCore offers a systemic "buckshot" approach to therapy via vagus nerve stimulation, unlike pharmaceutical "sniper shot" gene inhibitors; Quell is the sole product for fibromyalgia.
• Intellectual Property: Holds ~250 patents covering cervical non-invasive vagal nerve stimulation (80-90% of vagal fibers) and mobile app control technologies.

Risks and Challenges:

• Customer Concentration: Approximately 70% of revenue relies on the VA, creating dependence on a single customer segment despite diversification efforts.
• Regulatory Path: New indications (CIPN) require FDA approval and potential reimbursement strategy development.
• Operational Efficiency: Current sales and marketing spend is elevated at 60% of revenue, significantly higher than the 40-50% industry standard, though this is a target for improvement.
• Commercialization Speed: Expanding into the fragmented federal marketplace (1,300 locations across 170 customers) requires significant sales force deployment.

Management Commentary and Tone:

• Tone is confident and turnaround-oriented, emphasizing a shift from R&D-focused to commercial execution.
• Leadership change in April 2026 included new Co-CEO Mike Fox (35 years experience, 10-15 years in federal medical device sales) and the appointment of the current Co-CEO/CFO.
• Management stresses that the company is no longer a "single product, single customer" story but a multi-indication bioelectronic platform.
• Founders (Dr. Peter Stotz, Dr. Tom Errico) remain heavily invested and involved, aligning their interests with shareholders.

Analyst Questions and Answers:

• Break-even: Confirmed target is adjusted EBITDA positivity in the back half of 2027.
• Capital Requirements: Company is not currently seeking capital; focused on organic growth and stock buybacks.
• VA Penetration: Management estimates a "significant dent" in the VA market over the next two years via both legacy and new products.
• CIPN Protocol: The Quell device will likely be used preventatively and as needed, similar to the fibromyalgia protocol, pending approval.

Other Key Points:

• The company acquired Neurometrics in May 2025, which was generating ~$50,000/month in revenue at the time; it has since grown to $1.3 million quarterly.
• A major commercial milestone was secured in late 2025 with inclusion on formulary and contract with Kaiser Permanente (12.5 million lives).
• TACSTIM was specifically engineered for military durability (tank-resistant) and simplicity (3-button interface) for special operations and drone pilots.
• The stock has appreciated 71-72% since December 2025, with a peak high of 182% year-over-year growth.